← Back to Screener
Vor Biopharma Inc. Common Stock (VOR)
Price$14.57
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)102.29%
Price vs S&P 500 (4W)3.11%
VGM Score73.76
Market Capitalization$737.09M
All Metrics
Book Value / Share (Quarterly)$10.58
P/TBV (Annual)0.50x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.78
Price vs S&P 500 (YTD)3.52%
EPS (TTM)$-293.09
10-Day Avg Trading Volume0.80M
EPS Excl Extra (TTM)$-293.09
EPS (Annual)$-70.50
ROI (Annual)-120.95%
Cash / Share (Quarterly)$9.07
ROA (Last FY)-149.96%
EBITD / Share (TTM)$-19.48
ROE (5Y Avg)-71.50%
Cash Flow / Share (Annual)$-3.71
P/B Ratio11.16x
P/B Ratio (Quarterly)1.36x
Net Income / Employee (Annual)$-9,157,600
Net Interest Coverage (TTM)-24.81x
ROA (TTM)-261.17%
EPS Incl Extra (Annual)$-70.50
Current Ratio (Annual)18.20x
Quick Ratio (Quarterly)30.75x
3-Month Avg Trading Volume0.94M
52-Week Price Return283.85%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.58
52-Week High$65.80
EPS Excl Extra (Annual)$-70.50
CapEx CAGR (5Y)-25.72%
26-Week Price Return118.22%
Quick Ratio (Annual)18.15x
13-Week Price Return-5.85%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)31.15x
Enterprise Value$567.22M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$11.76
3-Month Return Std Dev84.12%
Net Income / Employee (TTM)$-11,619,500
ROE (Last FY)-120.95%
EPS Basic Excl Extra (Annual)$-70.50
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-293.09
ROI (TTM)-142.13%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.80
Price vs S&P 500 (52W)255.64%
Year-to-Date Return14.45%
5-Day Price Return4.47%
EPS Normalized (Annual)$-70.50
ROA (5Y Avg)-70.09%
Month-to-Date Return4.47%
Cash Flow / Share (TTM)$-1.82
EBITD / Share (Annual)$-37.35
ROI (5Y Avg)-71.50%
EPS Basic Excl Extra (TTM)$-293.09
P/TBV (Quarterly)0.71x
P/B Ratio (Annual)0.79x
Book Value / Share (Annual)$15.49
Price vs S&P 500 (13W)-15.60%
Beta1.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-142.13%
52-Week Low$3.38
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-5.11est. -0.79
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.18
4.18
4.23
4.23
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VORVor Biopharma Inc. Common Stock | — | — | B | $14.57 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Vor Biopharma is a clinical-stage cell therapy company developing engineered cell therapies for hematological malignancies using proprietary patient engineering technology. The company's lead programs include VCAR33 and Tremcel, with additional candidates targeting CD123, CLL1, and EMR2 markers for blood cancers and myelodysplastic syndrome.